An update from Aura Biosciences Inc ( (AURA) ) is now available.
Aura Biosciences has announced promising early data from its Phase 1 trial of bel-sar in treating non-muscle-invasive bladder cancer, with clinical responses observed in a subset of patients. The trial, aiming to evaluate the safety and biological activity of bel-sar, showed favorable safety results and potential for transforming cancer treatment. The company plans to expand its trials to further assess bel-sar’s impact, potentially positioning it as a novel treatment in urologic oncology.
See more insights into AURA stock on TipRanks’ Stock Analysis page.
